or Try an Advanced Search...

    Treatment Of Hemophilia Stocks List

    Symbol Grade Name % Change
    CNTA D Centessa Pharmaceuticals plc -0.11
    BIIB D Biogen Idec Inc. 3.18
    ALNY F Alnylam Pharmaceuticals, Inc. -0.28
    QURE F uniQure N.V. -0.22
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Hemophilia Acute Intermittent Porphyria Biopharmaceutical Biotechnology Clinical Development Deficiency Hemophilia A Idiopathic Pulmonary Fibrosis Lupus Spinal Muscular Atrophy Adeno Associated Virus Alipogene Tiparvovec Alnylam Pharmaceuticals Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency Alzheimer's Disease Amyloid Amyloidosis Antitrypsin Deficiency Applied Genetics

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Hemophilia stocks.

    Symbol Grade Name Weight
    BIS B ProShares UltraShort Nasdaq Biotechnology 8.07
    FBT D First Trust Amex Biotech Index Fund 6.57
    GERM D ETFMG Treatments Testing and Advancements ETF 6.36
    BBH D Market Vectors Biotech ETF 6.3
    IBBQ D Invesco Nasdaq Biotechnology ETF 5.29
    View all Treatment Of Hemophilia ETFs...
    Compare ETFs
    Compare BIS to BBH Compare GERM to BBH Compare GERM to IBBQ

        Treatment Of Hemophilia Stocks Recent News

        Date Stock Title
        Apr 26 BIIB Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
        Apr 26 BIIB The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
        Apr 26 BIIB Decoding Biogen Inc (BIIB): A Strategic SWOT Insight
        Apr 25 BIIB Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
        Apr 25 BIIB Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
        Apr 25 BIIB Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript
        Apr 25 BIIB Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year
        Apr 25 BIIB For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Do
        Apr 25 BIIB Q1 2024 Biogen Inc Earnings Call
        Apr 24 BIIB Why Biogen Stock Leaped Nearly 5% Higher Today
        Apr 24 CNTA Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
        Apr 24 BIIB Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
        Apr 24 BIIB Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
        Apr 24 BIIB Biogen (BIIB) Q1 2024 Earnings Call Transcript
        Apr 24 BIIB Biogen: Don’t expect any big acquisitions this year
        Apr 24 BIIB Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
        Apr 24 BIIB Biogen Stock Rises After Earnings, Jump in Sales of Alzheimer’s Drug
        Apr 24 BIIB Biogen stock rises on Q1 results, Alzheimer's drug sales
        Apr 24 BIIB Biogen Affirms Guidance After Mixed First Quarter
        Apr 24 BIIB Alzheimer’s Drug Leqembi Sees Sales Pickup, Boosting Biogen Stock
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Hemophilia Acute Intermittent Porphyria Biopharmaceutical Biotechnology Clinical Development Deficiency Hemophilia A Idiopathic Pulmonary Fibrosis Lupus Spinal Muscular Atrophy Adeno Associated Virus Alipogene Tiparvovec Alnylam Pharmaceuticals Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency Alzheimer's Disease Amyloid Amyloidosis Antitrypsin Deficiency Applied Genetics
        Treatment Of Hemophilia

        Treatment of hemophilia typically involves the use of replacement therapy, which involves infusions of clotting factor concentrates. These concentrates are made from donated human plasma and are designed to replace the missing clotting factor in the blood. Other treatments may include physical therapy, medications to reduce pain and swelling, and surgery to repair damaged joints.

        Browse All Tags